LUMICKS provides single-molecule analysis technologies for cancer research and immunotherapy.
LUMICKS has raised $21.9M in total funding. The most recent round was Debt Financing. The last funding was announced in October 2024.
LUMICKS's investors include European Investment Bank, SoftBank Vision Fund, T. Rowe Price, Lauxera Capital Partners, Gilde Healthcare.
LUMICKS is headquartered in Amsterdam, The Netherlands.
LUMICKS provides single-molecule analysis technologies for cancer research and immunotherapy.
LUMICKS is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LUMICKS — Funding & Investors." VCBacked, October 10, 2024, https://www.vcbacked.co/company/lumicks. Accessed September 30, 2026.
VCBacked. (2024). LUMICKS — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/lumicks
{{cite web |title=LUMICKS — Funding & Investors |url=https://www.vcbacked.co/company/lumicks |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated